| JIANGSU-HAOSOH-PHARMACEUTICAL-GROUP-CO-LTD |
JIANGSU-HAOSOH-PHARMACEUTICAL-GROUP-CO-LTD |
85%
|
lity reasons. For other products under direct sales, we generally allow customers to return unused goods within seven days and to exchange defective goods. In respect of products of which we manage i… |
| PHARMACEUTICAL-CO-LTD |
PHARMACEUTICAL-CO-LTD |
85%
|
yang Pharmaceutical Co., Ltd., accounted for 39.1% of our total purchases. For the year ended December 31, 2025, two suppliers, namely Dongguan Chaoyang Pharmaceutical Co., Ltd. and Guangzhou Guoying… |
| CHAOYANG-PHARMACEUTICAL-CO-LTD |
CHAOYANG-PHARMACEUTICAL-CO-LTD |
62%
|
ngguan Chaoyang Pharmaceutical Co., Ltd. and Guangzhou Suize Pharmaceutical Co., Ltd., collectively accounted for 44.0% of our total purchases. For the year ended December 31, 2024, one supplier, nam… |
| CO-LTD |
CO-LTD |
62%
|
utical Co., Ltd., collectively accounted for 44.0% of our total purchases. For the year ended December 31, 2024, one supplier, namely Dongguan Chaoyang Pharmaceutical Co., Ltd., accounted for 39.1% o… |
| GUANGZHOU-POMEGRANATE-CLOUD-MEDICAL-HEALTH-MEDIC |
GUANGZHOU-POMEGRANATE-CLOUD-MEDICAL-HEALTH-MEDIC |
62%
|
dit losses 1,488,459 841,683 ( 240,982 ) ( 34,460 ) Allowance for inventory 503,079 494,459 1,883,635 269,355 Share base payment — — 16,423,683 2,348,555 Impairment loss on long-lived assets 1,107,02… |
| GUANGZHOU-QILEKANG-DIGITAL-HEALTH-MEDICAL-TECHNO |
GUANGZHOU-QILEKANG-DIGITAL-HEALTH-MEDICAL-TECHNO |
62%
|
dit losses 1,488,459 841,683 ( 240,982 ) ( 34,460 ) Allowance for inventory 503,079 494,459 1,883,635 269,355 Share base payment — — 16,423,683 2,348,555 Impairment loss on long-lived assets 1,107,02… |
| GUANGZHOU-QILEKANG-MODERN-PHARMACEUTICAL-LOGISTI |
GUANGZHOU-QILEKANG-MODERN-PHARMACEUTICAL-LOGISTI |
62%
|
e an adverse effect on our business, financial condition and results of operations. The PRC anti-monopoly enforcement agencies have in recent years strengthened enforcement under the PRC Anti-monopol… |
| GUANGZHOU-QILEKANG-PHARMACEUTICAL-CHAIN-CO-LTD |
GUANGZHOU-QILEKANG-PHARMACEUTICAL-CHAIN-CO-LTD |
62%
|
ily attributable to our net loss of RMB36.9 million, as adjusted by the reconciliation of net loss to net cash used in operating activities, which primarily comprised (i) changes in expected credit l… |
| HANGZHOU-QILEKANG-PHARMACEUTICAL-CO-LTD |
HANGZHOU-QILEKANG-PHARMACEUTICAL-CO-LTD |
62%
|
e an adverse effect on our business, financial condition and results of operations. The PRC anti-monopoly enforcement agencies have in recent years strengthened enforcement under the PRC Anti-monopol… |
| INDUSTRIAL-BANK-CO-LTD |
INDUSTRIAL-BANK-CO-LTD |
62%
|
ily attributable to our net loss of RMB36.9 million, as adjusted by the reconciliation of net loss to net cash used in operating activities, which primarily comprised (i) changes in expected credit l… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
e an adverse effect on our business, financial condition and results of operations. The PRC anti-monopoly enforcement agencies have in recent years strengthened enforcement under the PRC Anti-monopol… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
e an adverse effect on our business, financial condition and results of operations. The PRC anti-monopoly enforcement agencies have in recent years strengthened enforcement under the PRC Anti-monopol… |
| SHANGHAI-PUDONG-DEVELOPMENT-BANK-INDUSTRIAL-BANK |
SHANGHAI-PUDONG-DEVELOPMENT-BANK-INDUSTRIAL-BANK |
62%
|
ily attributable to our net loss of RMB36.9 million, as adjusted by the reconciliation of net loss to net cash used in operating activities, which primarily comprised (i) changes in expected credit l… |
| SUZHOU-CO-LTD |
SUZHOU-CO-LTD |
62%
|
lity reasons. For other products under direct sales, we generally allow customers to return unused goods within seven days and to exchange defective goods. In respect of products of which we manage i… |
| U-S-PUBLIC-COMPANY |
U-S-PUBLIC-COMPANY |
62%
|
er PRC laws and regulations, all advertisements published online containing drug names, applicable symptoms treated by such drugs (major functions) or other drug-related content, and advertisements p… |
| XIAMEN-AMOYTOP-BIOTECH-CO-LTD-SHENYANG-SINQI-PHA |
XIAMEN-AMOYTOP-BIOTECH-CO-LTD-SHENYANG-SINQI-PHA |
62%
|
lity reasons. For other products under direct sales, we generally allow customers to return unused goods within seven days and to exchange defective goods. In respect of products of which we manage i… |
